A Phase 3 Study of Zalunfiban in Subjects With ST-elevation MI

A phase 3 trial registered on ClinicalTrials.gov. The registry status is active, not recruiting. It enrolled 2463 participants.

Also called NCT04825743

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 2,463 participants (enrolled count) (from the registry)
Sponsor
CeleCor Therapeutics (from the registry)
Registry
  • NCT NCT04825743
Other papers using this trial's data
  • The effect of zalunfiban on high sensitivity cardiac troponin and the association with clinical outcomes in patients with STEMI American heart journal, 2026-11 DOI, PubMed 42303064

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
United States, Canada, Czechia, France, Hungary, Mexico, Netherlands, Romania (from the registry)
Registry status
  • Active, not recruiting (from the registry)

Technical summary

Registry record NCT04825743. Randomized; quadruple masking; primary purpose treatment. Start 2021-04-24 (actual); primary completion 2026-05-13 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Phase 3 Study of Zalunfiban in Subjects With ST-elevation MI
Acronym
CELEBRATE
Condition
ST-elevation Myocardial Infarction (STEMI)
Intervention (Drug)
zalunfiban
Intervention (Drug)
Placebo
Lead sponsor
CeleCor Therapeutics (class: industry)

Record details

Record id
cardio:ct-nct04825743
Content hash
c1b40e46d60959f3bf775273197e83e8aaed198eb7c73d36e428e4f087b7c2af